Form 4 for ERNA Ernexa Therapeutics Inc.
Accepted 2025-07-07 00:00:00 ET · period of report 2025-06-21 · accession 0001641172-25-018063 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-07-07 | 2025-06-21 | ERNA | Gurrola Sandra M | SVP of Fin | M - OptEx | — | +30 | 110 | +38% | — |
| D | 2025-07-07 | 2025-06-21 | ERNA | Gurrola Sandra M | SVP of Fin | M - OptEx | $0.00 | +30 | 0 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-21 | M | A | 30 | — | 110 | D | — | — | (F1) Each restricted stock unit converts into one share of common stock. |
| 2 | Derivative | Restricted Stock Units | 2025-06-21 | M | A | 30 | $0.00 | 0 | D | — · — to — | 30 Common Stock | (F1) Each restricted stock unit converts into one share of common stock. (F2) On June 21, 2021, the reporting person was granted 118 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date. |